$6.54
2.10% yesterday
Nasdaq, Nov 12, 10:15 pm CET
ISIN
US62855J1043
Symbol
MYGN

Myriad Genetics, Inc. Stock price

$6.54
-1.30 16.58% 1M
+2.29 53.88% 6M
-7.17 52.30% YTD
-9.63 59.55% 1Y
-13.81 67.86% 3Y
-10.16 60.84% 5Y
-36.33 84.74% 10Y
-2.81 30.05% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
-0.14 2.10%

Key metrics

Basic
Market capitalization
$609.6m
Enterprise Value
$583.7m
Net debt
positive
Cash
$145.4m
Shares outstanding
93.1m
Valuation (TTM | estimate)
P/E
negative | 1,387.8
P/S
0.7 | 0.7
EV/Sales
0.7 | 0.7
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
68.2%
Return on Equity
-18.2%
ROCE
-14.2%
ROIC
-14.8%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$825.3m | $838.1m
EBITDA
$-25.8m | $29.2m
EBIT
$-82.1m | $5.3m
Net Income
$-400.5m | $440.0k
Free Cash Flow
$-29.6m
Growth (TTM | estimate)
Revenue
0.2% | 0.1%
EBITDA
23.0% | 208.9%
EBIT
13.2% | 106.1%
Net Income
-244.7% | 100.4%
Free Cash Flow
72.4%
Margin (TTM | estimate)
Gross
70.4%
EBITDA
-3.1% | 3.5%
EBIT
-10.0%
Net
-48.5% | 0.1%
Free Cash Flow
-3.6%
More
EPS
$-4.3
FCF per Share
$-0.3
Short interest
10.8%
Employees
3k
Rev per Employee
$310.0k
Show more

Is Myriad Genetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Myriad Genetics, Inc. forecast:

3x Buy
16%
10x Hold
53%
6x Sell
32%

Analyst Opinions

19 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy
16%
Hold
53%
Sell
32%

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
825 825
0% 0%
100%
- Direct Costs 245 245
4% 4%
30%
581 581
2% 2%
70%
- Selling and Administrative Expenses 549 549
2% 2%
67%
- Research and Development Expense 114 114
12% 12%
14%
-26 -26
23% 23%
-3%
- Depreciation and Amortization 56 56
8% 8%
7%
EBIT (Operating Income) EBIT -82 -82
13% 13%
-10%
Net Profit -401 -401
245% 245%
-49%

In millions USD.

Don't miss a Thing! We will send you all news about Myriad Genetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Myriad Genetics, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.
Positive
Seeking Alpha
8 days ago
Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, but revenue gains remain modest and expansion impacts are delayed. Upcoming addition launches, including expanded MyRisk HCT and AI-powered Prolaris, offer potential but won't affect results until m...
Neutral
Seeking Alpha
9 days ago
Myriad Genetics, Inc. ( MYGN ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Mark Verratti - Chief Operating Officer Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division David Westenberg - P...
More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Samraat Raha
Employees 2,700
Founded 1991
Website myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today